Increased formation of α-synuclein oligomers in plasma of patients with Parkinson’s disease

doi:10.3969/j.issn.1006-7795.2013.06.012

Abstract

Abstract:

Objective To study the effect of plasma of patients with Parkinson's disease(PD) on the formation of oligomeric α-synuclein (α-Syn). Methods Recombinant α-Syn was incubated in the plasma of PD patients and normal subjects. Immunoblotting analysis was used to identify the formation of α-Syn oligomers. A special ELISA method was used to evaluate the amount of α-Syn oligomers formed in PD and control plasma. Results The amount of α-Syn oligomer formed in the plasma of PD patients was higher than that in control plasma. Conclusion Compared with control plasma, the plasma from PD patients enhanced the oligomerization of α-Syn.

Key words: Parkinson's disease, plasma, α-synuclein(α-Syn), oligomers

CLC Number:

R338

YIN Na, CHEN Yudong, LI Xin, YANG Weiwei, LI Xuran, YU Shun. Increased formation of α-synuclein oligomers in plasma of patients with Parkinson’s disease[J]. Journal of Capital Medical University, 2013, 34(6): 840-843.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/10.3969/j.issn.1006-7795.2013.06.012

https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/Y2013/V34/I6/840

References

[1] Alberio T, Fasano M. Proteomics in Parkinson's disease: An unbiased approach towards peripheral biomarkers and new therapies[J]. J Biotechnol, 2010, 156 (4):325-337.
[2] Braak H, Ghebremedhin E, Rüb U, et al. Stages in the development of Parkinson's disease-related pathology[J]. Cell Tissue Res, 2004, 318 (1):121-134.
[3] Klos K J, Ahlskog J E, Josephs K A, et al. Alpha-synuclein pathology in the spinal cords of neurologically asymptomatic aged individuals[J]. Neurology, 2006, 66 (7):1100-1102.
[4] Cersosimo M G, Benarroch E E. Neural control of the gastrointestinal tract: implications for Parkinson disease[J]. Mov Disord, 2008, 23(8):1065-1075.
[5] Paleologou K E, Kragh C L, Mann D M, et al. Detection of elevated levels of soluble alpha-synuclein oligomers in post-mortem brain extracts from patients with dementia with Lewy bodies[J]. Brain, 2009, 132(Pt 4):1093-1101.
[6] El-Agnaf O M, Salem S A, Paleologou K E, et al. Detection of oligomeric forms of alpha-synuclein protein in human plasma as a potential biomarker for Parkinson's disease[J]. FASEB J, 2006, 20(3):419-425.
[7] 李雁, 殷娟娟, 李昕, 等.α-突触核蛋白寡聚体对多巴胺能神经细胞线粒体膜电位的影响[J].中国现代神经疾病杂志, 2008, 8:26-31.
[8] Ono K, Noguchi-Shinohara M, Yoshita M, et al. Cerebrospinal fluid of Alzheimer's disease and dementia with Lewy bodies patients enhances alpha-synuclein fibril formation in vitro[J]. Exp Neurol, 2007, 203(2):579-583.
[9] Ilic T V, Jovanovic M, Jovicic A, et al. Oxidative stress indicators are elevated in de novo Parkinson's disease patients[J]. Funct Neurol, 1999, 14(3):141-147.
[11] 程芙蓉, 李昕, 殷娟娟, 等.过氧化氢和帕金森病患者血清促进α-突触核蛋白向线粒体与细胞核转运[J].首都医科大学学报, 2010, 31(6):732-736.
[10] Dexter D T, Carter C J, Wells F R, et al. Basal lipid peroxidation in substantia nigra is increased in Parkinson's disease[J]. J Neurochem, 1989, 52(2):381-389.
[12] Prakash K M, Tan E K. Development of Parkinson's disease biomarkers[J]. Expert Rev Neurother, 2010, 10(12):1811-1825.
[13] Lee P H, Lee G, Park H J, et al. The plasma alpha-synuclein levels in patients with Parkinson's disease and multiple system atrophy[J]. J Neural Transm, 2006, 113(10):1435-1439.
[14] Duran R, Barrero F J, Morales B, et al. Plasma alpha-synuclein in patients with Parkinson's disease with and without treatment[J]. Mov Disord, 2010, 25(4):489-493.
[15] Bruggink K A, Kuiperij H B, Ekholm-Pettersson F, et al. Detection of elevated levels of α-synuclein oligomers in CSF from patients with Parkinson disease[J]. Neurology, 2011, 77(5):510-511.